Acetylcysteine and budesonide for the treatment of refractory Mycoplasma pneumoniae pneumonia in children: a clinical observation.
Acetylcysteine
Bronchoscopic alveolar lavage
Children
Refractory Mycoplasma pneumoniae pneumonia
Journal
Italian journal of pediatrics
ISSN: 1824-7288
Titre abrégé: Ital J Pediatr
Pays: England
ID NLM: 101510759
Informations de publication
Date de publication:
08 Jul 2023
08 Jul 2023
Historique:
received:
21
12
2022
accepted:
30
06
2023
medline:
10
7
2023
pubmed:
9
7
2023
entrez:
8
7
2023
Statut:
epublish
Résumé
To examine the clinical impact of bronchoscope alveolar lavage (BAL) combination with budesonide, ambroxol + budesonide, or acetylcysteine + budesonide in the treatment of refractory Mycoplasma pneumoniae pneumonia (RMPP). Eighty-two RMPP patients admitted to Pediatrics at The First People's Hospital of Zhengzhou were retrospectively evaluated between August 2016 and August 2019. All patients were administered BAL in addition to intravenous Azithromycin, expectoration, and nebulizer inhalation. The medications added to the BLA separated the patients into the Budesonide group, Ambroxol + budesonide group, and acetylcysteine + budesonide group. Analyzed were the variations in laboratory examination indices, improvement in lung imaging, overall effective rate, and adverse responses in the three groups. The laboratory test indices of patients in all three groups improved significantly relative to pre-treatment levels, and the results were statistically significant. After therapy, there were no significant differences between the three groups in terms of white blood cell (WBC), C-reactive protein (CRP), or erythrocyte sedimentation rate (ESR). Serum lactate dehydrogenase (LDH) and serum ferritin (SF) varied significantly across the three groups (P < 0.05). In the acetylcysteine + budesonide group, the absorption rate of lung imaging lesions and clinical efficacy were superior to those of the other two groups. There were no significant differences between the three groups in the occurrence of adverse events (P > 0.05). BLA-coupled acetylcysteine + budesonide was superior to the other two groups in enhancing the effectiveness of RMPP in children, which might increase lung opacity absorption and minimize lung inflammation.
Sections du résumé
BACKGROUND
BACKGROUND
To examine the clinical impact of bronchoscope alveolar lavage (BAL) combination with budesonide, ambroxol + budesonide, or acetylcysteine + budesonide in the treatment of refractory Mycoplasma pneumoniae pneumonia (RMPP).
METHODS
METHODS
Eighty-two RMPP patients admitted to Pediatrics at The First People's Hospital of Zhengzhou were retrospectively evaluated between August 2016 and August 2019. All patients were administered BAL in addition to intravenous Azithromycin, expectoration, and nebulizer inhalation. The medications added to the BLA separated the patients into the Budesonide group, Ambroxol + budesonide group, and acetylcysteine + budesonide group. Analyzed were the variations in laboratory examination indices, improvement in lung imaging, overall effective rate, and adverse responses in the three groups.
RESULTS
RESULTS
The laboratory test indices of patients in all three groups improved significantly relative to pre-treatment levels, and the results were statistically significant. After therapy, there were no significant differences between the three groups in terms of white blood cell (WBC), C-reactive protein (CRP), or erythrocyte sedimentation rate (ESR). Serum lactate dehydrogenase (LDH) and serum ferritin (SF) varied significantly across the three groups (P < 0.05). In the acetylcysteine + budesonide group, the absorption rate of lung imaging lesions and clinical efficacy were superior to those of the other two groups. There were no significant differences between the three groups in the occurrence of adverse events (P > 0.05).
CONCLUSIONS
CONCLUSIONS
BLA-coupled acetylcysteine + budesonide was superior to the other two groups in enhancing the effectiveness of RMPP in children, which might increase lung opacity absorption and minimize lung inflammation.
Identifiants
pubmed: 37422684
doi: 10.1186/s13052-023-01491-y
pii: 10.1186/s13052-023-01491-y
pmc: PMC10329323
doi:
Substances chimiques
Acetylcysteine
WYQ7N0BPYC
Budesonide
51333-22-3
Ambroxol
200168S0CL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
80Informations de copyright
© 2023. The Author(s).
Références
Rev Mal Respir. 2020 Oct;37(8):652-661
pubmed: 32888730
Cureus. 2020 Oct 24;12(10):e11122
pubmed: 33133790
Respir Res. 2019 Aug 23;20(1):193
pubmed: 31443650
J Trop Pediatr. 2021 Jan 29;67(1):
pubmed: 33575805
J Infect Chemother. 2014 Apr;20(4):270-3
pubmed: 24486173
J Infect. 2008 Sep;57(3):223-8
pubmed: 18656264
BMC Infect Dis. 2020 Aug 26;20(1):633
pubmed: 32847534
Ann Otol Rhinol Laryngol. 2021 Feb;130(2):161-166
pubmed: 32672052
J Clin Med. 2022 May 17;11(10):
pubmed: 35628949
Einstein (Sao Paulo). 2018 Nov 08;16(4):eAO4380
pubmed: 30427487
BMC Infect Dis. 2021 Oct 21;21(1):1085
pubmed: 34674642
BMC Infect Dis. 2021 Jan 28;21(1):126
pubmed: 33509121
Paediatr Respir Rev. 2006 Dec;7(4):288-92
pubmed: 17098644
Front Pediatr. 2022 Oct 10;10:946579
pubmed: 36299699
Pathogens. 2021 Jan 25;10(2):
pubmed: 33503845
Zhonghua Er Ke Za Zhi. 2013 Oct;51(10):745-52
pubmed: 24406226
Ther Adv Infect Dis. 2021 Aug 18;8:20499361211037168
pubmed: 34422266
J Thorac Dis. 2016 Dec;8(12):3826-3837
pubmed: 28149583